Biogen (BIIB) Operating Leases (2019 - 2026)

Biogen has reported Operating Leases for 8 years, with the latest figure at $264.8 million in Q2 2026.

• On a quarterly basis, Operating Leases fell 14.83% year-over-year to $264.8 million in Q2 2026; TTM through Jun 2026 was $264.8 million, a 14.83% decrease from a year earlier, with the FY2025 full-year figure at $290.4 million, down 31.0% from the prior year.
• Operating Leases was $264.8 million for Q2 2026 at Biogen, down from $273.4 million in the prior quarter.
• The five-year high for Operating Leases was $490.3 million in Q4 2023, with the low at $264.8 million in Q2 2026.
• Average Operating Leases over 5 years is $346.8 million, with a median of $325.2 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Leases climbed 24.31% in 2024, then slumped 31.0% in 2025.
• Over 5 years, Operating Leases stood at $430.2 million in 2022, then climbed by 13.97% to $490.3 million in 2023, then declined by 14.15% to $420.9 million in 2024, then plunged by 31.0% to $290.4 million in 2025, then dropped by 8.82% to $264.8 million in 2026.
• The last three Operating Leases figures came in at $264.8 million (Q2 2026), $273.4 million (Q1 2026), and $290.4 million (Q4 2025), per Business Quant data.